1. Home
  2. SOPH

as of 04-17-2026 10:08am EST

$5.19
+$0.07
+1.37%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

Founded: 2011 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 367.7M IPO Year: 2021
Target Price: $7.50 AVG Volume (30 days): 87.2K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $2.58 - $5.70 Next Earning Date: 05-05-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 23.09% Revenue Growth (next year): 19.57%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered SOPH Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 15 hours ago

AI Recommendation

hold
Model Accuracy: 62.42%
62.42%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of SOPHiA GENETICS SA (SOPH)

Camblong Jurgi

Chief Executive Officer

Sell
SOPH Apr 15, 2026

Avg Cost/Share

$5.00

Shares

17,473

Total Value

$87,401.69

Owned After

3,646,967

SEC Form 4

Camblong Jurgi

Chief Executive Officer

Sell
SOPH Apr 14, 2026

Avg Cost/Share

$4.96

Shares

43,129

Total Value

$213,833.58

Owned After

3,646,967

SEC Form 4

Menu Philippe

Chief Medical Officer

Sell
SOPH Apr 14, 2026

Avg Cost/Share

$4.96

Shares

1,600

Total Value

$7,932.96

Owned After

266,996

SEC Form 4

Xu Zhenyu

Chief Scientific Officer

Sell
SOPH Apr 14, 2026

Avg Cost/Share

$4.97

Shares

600

Total Value

$2,979.78

Owned After

631,496

SEC Form 4

Muken Ross

President

Sell
SOPH Apr 14, 2026

Avg Cost/Share

$4.96

Shares

2,800

Total Value

$13,887.16

Owned After

682,432

SEC Form 4

Camblong Jurgi

Chief Executive Officer

Sell
SOPH Apr 13, 2026

Avg Cost/Share

$4.76

Shares

4,399

Total Value

$20,957.28

Owned After

3,646,967

SEC Form 4

Menu Philippe

Chief Medical Officer

Sell
SOPH Apr 13, 2026

Avg Cost/Share

$4.76

Shares

4,400

Total Value

$20,962.48

Owned After

266,996

Xu Zhenyu

Chief Scientific Officer

Sell
SOPH Apr 13, 2026

Avg Cost/Share

$4.76

Shares

4,414

Total Value

$21,026.97

Owned After

631,496

Muken Ross

President

Sell
SOPH Apr 13, 2026

Avg Cost/Share

$4.77

Shares

4,442

Total Value

$21,166.13

Owned After

682,432

SEC Form 4

Van Well Daan

Chief Legal Officer

Sell
SOPH Apr 10, 2026

Avg Cost/Share

$4.67

Shares

2,400

Total Value

$11,201.28

Owned After

346,420

SEC Form 4

Share on Social Networks: